Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q3 2022 (← Previous) (Next →)

Filing Date: Nov 10, 2022

Total Value: $58.66M (100.0% shares, 0.0% debt)

Holdings (8)

CRSP CRISPR Therapeutics AG 55.5%

Value $32.58M Shares 498,558 Est. Cost $40.26 Unrealized +80.0%

— Gritstone Oncology, Inc. 15.6%

Value $9.152M Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Passage Bio, Inc. 10.6%

Value $6.2M Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Adverum Biotechnologies, Inc. 8.2%

Value $4.815M Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Aligos Therapeutics, Inc. 4.4%

Value $2.552M Shares 2,320,381 Est. Cost $27.65 Unrealized —

— CymaBay Therapeutics, Inc. 3.2%

Value $1.903M Shares 543,753 Est. Cost $9871.60 Unrealized —

— Minerva Surgical Inc. 2.3%

Value $1.331M Shares 1,673,700 Est. Cost $5.14 Unrealized —

— Clovis Oncology, Inc. 0.2%

Value $121K Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$32.58M	55.5%	$40.26	+80.0%	Common Shares	H17182108
—	Gritstone Oncology, Inc.	3,561,150	$9.152M	15.6%	$7767.86	—	Common Stock	39868T105
—	Passage Bio, Inc.	4,959,769	$6.2M	10.6%	$17.48	—	Common Stock	702712100
—	Adverum Biotechnologies, Inc.	5,068,233	$4.815M	8.2%	$9646.10	—	Common Stock	00773U108
—	Aligos Therapeutics, Inc.	2,320,381	$2.552M	4.4%	$27.65	—	Common Stock	01626L105
—	CymaBay Therapeutics, Inc.	543,753	$1.903M	3.2%	$9871.60	—	Common Stock	23257D103
—	Minerva Surgical Inc.	1,673,700	$1.331M	2.3%	$5.14	—	Common Stock	60343F106
—	Clovis Oncology, Inc.	101,855	$121K	0.2%	$56000.00	—	Common Stock	189464100